(Q46013031)

English

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

scientific article published in January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. (English)

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

1 reference

based on heuristic

inferred from title

prostate carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

author name string

Jonathan E Rosenberg

1

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

Matthew D Galsky

2

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

Nicholas C Rohs

3

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

Vivian K Weinberg

4

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

W Kevin Kelly

6

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

Eric J Small

7

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

language of work or name

0 references

publication date

1 January 2006

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

106

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

1

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

58-62

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Epothilones: mechanism of action and biologic activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for metastatic breast cancer-report of a European expert panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Second line chemotherapy for NSCLC: establishing a gold standard

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21559

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21559

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

release_gphqfpr5xbbabkg7cibdckh4ha

1 reference

https://api.fatcat.wiki/v0/release/gphqfpr5xbbabkg7cibdckh4ha

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/16329138

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46013031&oldid=1840447276"